Amgen (AMGN) is facing a possible EU withdrawal of its rare-disorder therapy, Tavneos, after an expert panel of the European Medicines Agency recommended its ma...
Amgen (AMGN) is facing a potential withdrawal of its rare-disorder therapy, Tavneos, from the European Union market. This follows a recommendation from an expert panel of the European Medicines Agency. The development could significantly impact Amgen's pharmaceutical portfolio…
Market Samachar is a news aggregator. This article was originally published by seekingalpha.com. Tap the button above to read the full story on their site.